Showing 1-10 of 14 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Injectable Glucose-Responsive Hydrogels for Multi-Hormone Therapy | University of Notre Dame | Matthew Webber | Improving Lives | 01-March-2020 to 28-February-2026 | $750,000.00 |
| Evaluation of Oxidized Insulin as a Biomarker and Therapeutic Target in Type 1 Diabetes | Trustees of Indiana University | Amelia Linnemann | Cures | 01-October-2023 to 30-September-2025 | $560,000.00 |
| Defining the role of islet-derived extracellular vesicle PD-L1 cargo in type-1 diabetes | Trustees of Indiana University | Chaitra Rao | Cures | 01-March-2024 to 30-April-2027 | $228,537.45 |
| Targeting type 1 Diabetes through Polyamines with DFMO | Trustees of Indiana University | Emily Sims | Cures | 01-October-2022 to 30-September-2026 | $3,693,701.00 |
| Investigating Combinatorial Use of Inhibitors of Focal Adhesion Kinase and PFKFB3 for Reversal of Type 1 Diabetes | Trustees of Indiana University | Jon Piganelli | Cures | 01-August-2023 to 30-June-2025 | $334,595.29 |
| SOLUBLE LYMPHOCYTE ACTIVATION GENE-3 (s-LAG-3): A POTENTIAL SURROGATE MARKER FOR TYPE-1 DIABETES PROGRESSION AND IMMUNOTHERAPY SUCCESS | Trustees of Indiana University | Jon Piganelli | Cures | 01-July-2025 to 30-June-2026 | $153,000.00 |
| CGM-Derived Glucose Dynamic Index as Diagnostic Marker for Progression to Type 1 Diabetes | Trustees of Indiana University | Viral Shah | Cures | 01-November-2024 to 31-October-2027 | $900,000.00 |
| Relationship of Time-In-Range with microvascular complications in type 1 diabetes | Trustees of Indiana University | Viral Shah | Improving Lives | 01-February-2024 to 31-July-2025 | $71,123.95 |
| Safety and Efficacy of Adjunct Therapies in Adults with Type 1 diabetes: multicenter, registry-based study | Trustees of Indiana University | Viral Shah | Improving Lives | 01-September-2025 to 31-August-2028 | $1,603,777.39 |
| Preclinical evaluation of SERCA2 activators for pancreatic beta-cell protection in T1D | Neurodon LLC | Russell Dahl | Cures | 01-June-2022 to 31-October-2025 | $920,000.00 |